Credit Suisse Remains Cautious on Neurocrine Bio. (NBIX) Following Virtual Meeting
Tweet Send to a Friend
Credit Suisse analyst Evan Seigerman reiterated a Neutral rating and $90.00 price target on Neurocrine Bio. (NASDAQ: NBIX) noting that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
